Search Results - "Raskob, Gary. E."

Milvexian for the Prevention of Venous Thromboembolism by Weitz, Jeffrey I, Strony, John, Ageno, Walter, Gailani, David, Hylek, Elaine M, Lassen, Michael R, Mahaffey, Kenneth W, Notani, Ravi S, Roberts, Robin, Segers, Annelise, Raskob, Gary E

“…A phase 2 trial compared various doses of milvexian with standard enoxaparin for thromboprophylaxis after total knee replacement. Venous thromboembolism…”
Get full text

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism by Raskob, Gary E, van Es, Nick, Verhamme, Peter, Carrier, Marc, Di Nisio, Marcello, Garcia, David, Grosso, Michael A, Kakkar, Ajay K, Kovacs, Michael J, Mercuri, Michele F, Meyer, Guy, Segers, Annelise, Shi, Minggao, Wang, Tzu-Fei, Yeo, Erik, Zhang, George, Zwicker, Jeffrey I, Weitz, Jeffrey I, Büller, Harry R

“…In a randomized trial, 1050 patients with cancer who had acute venous thromboembolism were assigned to receive either dalteparin or edoxaban for 6 to 12…”
Get full text

Oral Apixaban for the Treatment of Acute Venous Thromboembolism by Agnelli, Giancarlo, Buller, Harry R, Cohen, Alexander, Curto, Madelyn, Gallus, Alexander S, Johnson, Margot, Masiukiewicz, Urszula, Pak, Raphael, Thompson, John, Raskob, Gary E, Weitz, Jeffrey I

“…In this multicenter trial, the oral factor Xa inhibitor apixaban was compared with enoxaparin and warfarin for the treatment of acute venous thromboembolism…”
Get full text

The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs by Grosse, Scott D, Nelson, Richard E, Nyarko, Kwame A, Richardson, Lisa C, Raskob, Gary E

“…Abstract Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is an important cause of preventable mortality and…”
Get full text

Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement by Lassen, Michael Rud, Raskob, Gary E, Gallus, Alexander, Pineo, Graham, Chen, Dalei, Portman, Ronald J

“…This noninferiority trial compared enoxaparin, a subcutaneously administered, low-molecular-weight heparin, with apixaban, an orally active inhibitor of factor…”
Get full text

Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement by Lassen, Michael Rud, Gallus, Alexander, Raskob, Gary E, Pineo, Graham, Chen, Dalei, Ramirez, Luz Margarita

“…In this clinical trial, apixaban, an oral factor Xa inhibitor, was shown to be superior to enoxaparin for the prevention of thromboembolism after hip…”
Get full text

New paradigms in venous thromboprophylaxis of medically ill patients by Spyropoulos, Alex C, Raskob, Gary E

“…Acutelly-ill hospitalised medical patients are at risk of venous thromboembolism (VTE), both in-hospital and in the immediate post-discharge period, and…”
Get more information

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial by Lassen, Michael Rud, Dr, Raskob, Gary E, PhD, Gallus, Alexander, MD, Pineo, Graham, MD, Chen, Dalei, PhD, Hornick, Philip, MD

“…Summary Background Low-molecular-weight heparins such as enoxaparin are preferred for prevention of venous thromboembolism after major joint replacement…”
Get full text

Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients by Spyropoulos, Alex C., Ageno, Walter, Albers, Gregory W., Elliott, C. Gregory, Halperin, Jonathan L., Hiatt, William R., Maynard, Gregory A., Steg, P. Gabriel, Weitz, Jeffrey I., Lu, Wentao, Spiro, Theodore E., Barnathan, Elliot S., Raskob, Gary. E.

“…Hospitalized acutely ill medical patients are at risk for fatal and major thromboembolic events. Whether use of extended-duration primary thromboprophylaxis…”
Get full text

Clinical features of paediatric pulmonary hypertension: a registry study by Berger, Rolf MF, Prof, Beghetti, Maurice, Prof, Humpl, Tilman, MD, Raskob, Gary E, MD, Ivy, D Dunbar, MD, Jing, Zhi-Cheng, MD, Bonnet, Damien, MD, Schulze-Neick, Ingram, MD, Barst, Robyn J, Prof

“…Summary Background Paediatric pulmonary hypertension, is an important cause of morbidity and mortality, and is insufficiently characterised in children. The…”
Get full text

Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies by Prins, Martin H, Lensing, Anthonie Wa, Bauersachs, Rupert, van Bellen, Bonno, Bounameaux, Henri, Brighton, Timothy A, Cohen, Alexander T, Davidson, Bruce L, Decousus, Hervé, Raskob, Gary E, Berkowitz, Scott D, Wells, Philip S

“…Standard treatment for venous thromboembolism (VTE) consists of a heparin combined with vitamin K antagonists. Direct oral anticoagulants have been…”
Get full text

Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study by Spyropoulos, Alex C., Lipardi, Concetta, Xu, Jianfeng, Lu, Wentao, Suh, Eunyoung, Yuan, Zhong, Levitan, Bennett, Sugarmann, Chiara, De Sanctis, Yoriko, Spiro, Theodore E., Barnathan, Elliot S., Raskob, Gary E.

“…Acutely ill medical patients are at risk of venous thromboembolism (VTE) and VTE-related mortality during hospitalization and posthospital discharge, but…”
Get full text

Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial by Raskob, Gary E, Prof, van Es, Nick, MD, Segers, Annelise, MD, Angchaisuksiri, Pantep, Prof, Oh, Doyeun, MD, Boda, Zoltan, Prof, Lyons, Roger M, MD, Meijer, Karina, Prof, Gudz, Ivan, Prof, Weitz, Jeffrey I, Prof, Zhang, George, PhD, Lanz, Hans, MD, Mercuri, Michele F, MD, Büller, Harry R, Prof

“…Summary Background Venous thromboembolism occurs commonly in patients with cancer. Direct oral anticoagulants are non-inferior to conventional anticoagulants…”
Get full text

Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients by Raskob, Gary E, Spyropoulos, Alex C, Cohen, Alexander T, Weitz, Jeffrey I, Ageno, Walter, De Sanctis, Yoriko, Lu, Wentao, Xu, Jianfeng, Albanese, John, Sugarmann, Chiara, Weber, Traci, Lipardi, Concetta, Spiro, Theodore E, Barnathan, Elliot S

“…Background Asymptomatic proximal deep vein thrombosis (DVT) is an end point frequently used to evaluate the efficacy of anticoagulant thromboprophylaxis in…”
Get full text

Global Burden of Thrombosis: Epidemiologic Aspects by Wendelboe, Aaron M, Raskob, Gary E

“…Thromboembolic conditions were estimated to account for 1 in 4 deaths worldwide in 2010 and are the leading cause of mortality. Thromboembolic conditions are…”
Get full text

Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial by Büller, Harry R, Prof, Gallus, Alex S, Prof, Pillion, Gerard, MD, Prins, Martin H, Prof, Raskob, Gary E, Prof

“…Summary Background Treatment of pulmonary embolism with low-molecular-weight heparin and vitamin K antagonists, such as warfarin, is not ideal. We aimed to…”
Get full text

Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group by Key, Nigel S, Khorana, Alok A, Mackman, Nigel, McCarty, Owen J T, White, Gilbert C, Francis, Charles W, McCrae, Keith R, Palumbo, Joseph S, Raskob, Gary E, Chan, Andrew T, Sood, Anil K

“…The risk for venous thromboembolism (VTE) is increased in cancer and particularly with chemotherapy, and it portends poorer survival among patients with…”
Get full text

ADAMTS13 activity in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients by Vesely, Sara K., George, James N., Lämmle, Bernhard, Studt, Jan-Dirk, Alberio, Lorenzo, El-Harake, Mayez A., Raskob, Gary E.

“…Initial management of patients with thrombotic thrombocytopenic purpura—hemolytic uremic syndrome (TTP-HUS) is difficult because of lack of specific diagnostic…”
Get full text

Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER by Raskob, Gary E, Spyropoulos, Alex C, Spiro, Theodore E, Lu, Wentao, Yuan, Zhong, Levitan, Bennett, Suh, Eunyoung, Barnathan, Elliot S

“…Background Thromboprophylaxis extended after hospital discharge in medically ill patients currently is not recommended by practice guidelines because of…”
Get full text

Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness by Raskob, Gary E., Ageno, Walter, Albers, Gregory, Elliott, C. Gregory, Halperin, Jonathan, Maynard, Gregory, Steg, Philippe Gabriel, Weitz, Jeffrey I., Albanese, John, Yuan, Zhong, Levitan, Bennett, Lu, Wentao, Suh, Eun Young, Spiro, Theodore, Lipardi, Concetta, Barnathan, Elliot S., Spyropoulos, Alex C.

“…Background Venous thromboembolism (VTE) often occurs after hospitalization in medically ill patients, but the population benefit–risk of extended…”
Get full text